238 related articles for article (PubMed ID: 14578913)
1. More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2).
Lip GY; Beevers DG
J Hum Hypertens; 2003 Nov; 17(11):747-50. PubMed ID: 14578913
[No Abstract] [Full Text] [Related]
2. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Julius S
Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
[TBL] [Abstract][Full Text] [Related]
3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?
Weber MA; Giles TD
Rev Cardiovasc Med; 2006; 7(2):45-54. PubMed ID: 16915123
[TBL] [Abstract][Full Text] [Related]
5. Blocking the renin-angiotensin-aldosterone system or lowering the blood pressure: does EUROPA help?
Mackay JA
J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):205-6. PubMed ID: 14689366
[TBL] [Abstract][Full Text] [Related]
6. [Historical perspective of renin-angiotensin system blocking in the treatment of arterial hypertension].
Coca A; Redón J
Med Clin (Barc); 1996 Mar; 106(12):457-9. PubMed ID: 8656731
[No Abstract] [Full Text] [Related]
7. [Hypertension in patients with diabetes].
Poulsen PL; Hansen KW; Gaede PH; Rossing P
Ugeskr Laeger; 2009 Jun; 171(24):2031-4. PubMed ID: 19523370
[TBL] [Abstract][Full Text] [Related]
8. Fewer mega-trials and more clinically oriented studies in hypertension research? The case of blocking the renin-angiotensin-aldosterone system.
Volpe M; Tocci G; Pagannone E
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S36-43. PubMed ID: 16565245
[TBL] [Abstract][Full Text] [Related]
9. Anti-diabetic effect of blockade of the renin-angiotensin system.
Ando K; Fujita T
Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting the renin-angiotensin system: why and in which patients.
Berra K; Miller NH
J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
[TBL] [Abstract][Full Text] [Related]
11. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
Abassi Z; Armaly Z; Nakhoul F; Hoffman A
Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
[TBL] [Abstract][Full Text] [Related]
12. Clinical trials in nephrology: success or failure.
Garcia-Donaire JA; Segura J; Ruilope LM
Curr Opin Nephrol Hypertens; 2007 Mar; 16(2):59-63. PubMed ID: 17293678
[TBL] [Abstract][Full Text] [Related]
13. The renin angiotensin system and cardiovascular disease: hope or hype?
Williams B
J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):142-6. PubMed ID: 11967805
[No Abstract] [Full Text] [Related]
14. Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events.
Papademetriou V
Am Heart J; 2009 Jun; 157(6 Suppl):S24-30. PubMed ID: 19450721
[TBL] [Abstract][Full Text] [Related]
15. ONTARGET still OFF-TARGET?
Lambers Heerspink HJ; de Zeeuw D
Circulation; 2011 Mar; 123(10):1049-51. PubMed ID: 21357820
[No Abstract] [Full Text] [Related]
16. Defining the role of renin/angiotensin-targeted antihypertensive therapy in decreasing cardiovascular risk: evidence, guideline evolution, and questions to be resolved.
Probstfield J
J Fam Pract; 2009 Jun; 58(6 Suppl):S1-8. PubMed ID: 19508849
[No Abstract] [Full Text] [Related]
17. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Lyle PA; Tershakovec AM; Devereux RB; Oparil S; Dahlöf B; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Wedel H
Expert Opin Emerg Drugs; 2005 Nov; 10(4):729-45. PubMed ID: 16262560
[TBL] [Abstract][Full Text] [Related]
18. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
19. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
Krum H; Gilbert RE
J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
[TBL] [Abstract][Full Text] [Related]
20. Preventing and reversing target organ damage by treatment of the renin-angiotensin system.
Krakoff LR; Rajasekharaiah V
Mt Sinai J Med; 1998 Mar; 65(2):125-32. PubMed ID: 9520516
[No Abstract] [Full Text] [Related]
[Next] [New Search]
